We designed our TROP2-TRACTr product candidate as a double-masked TRACTr in which the TROP2-binding domain and the T cell-specific binding domain (CD3e) is masked.
Improving upon prior approaches
Our TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target that is is overexpressed in various cancer types, such as breast, lung, urothelial, endometrial, ovarian, prostate, pancreatic, gastric, colon, head and neck, and glioma. TROP2 expression in cancer cells has long been correlated with drug resistance, and high levels of TROP2 expression have been shown to correlate with poor prognosis in a variety of cancer types.
Our TROP2-TRACTr had a half-life of 90 hours in NHPs, which we believe is in line with once-weekly dosing in humans
Dosing of our TROP2-TRACTr in NHPs had minimal effects on inflammatory cytokine levels. In contrast, dosing of a TROP2-TCE led to substantial levels of IL-6 as well as elevation of other inflammatory cytokines commonly observed in CRS